Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for kidney diseases. Founded in 2007 and headquartered in Cambridge, Massachusetts, the company targets conditions such as chronic kidney disease (CKD) and associated anemia. Its lead product, Auryxia, is a ferric citrate formulation used to manage serum phosphorus levels in adult patients with dialysis-dependent CKD and to treat iron deficiency anemia in those with non-dialysis-dependent CKD. Additionally, Akebia is advancing vadadustat, an oral therapy that is in Phase III development for treating anemia related to CKD in both dialysis-dependent and non-dialysis patients. The company maintains collaborative agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation to support the development and commercialization of vadadustat in various global markets. Through these efforts, Akebia aims to address critical unmet needs in renal therapeutics.